ReNAgade Therapeutics Appoints Paul Perreault to Board of Directors
Cambridge, Mass., December 5, 2023 – ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced the appointment of Paul Perreault to its Board of Directors,...
View ArticleReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare...
Cambridge, Mass., January 4, 2024 – ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will present at...
View ArticleReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech...
Cambridge, Mass., February 22, 2024 – ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will virtually...
View ArticleReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation...
Cambridge, Mass., February 27, 2024 – ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM...
View ArticleEvercore ISI 2024 Emerging Biotech Conference Webcast
February 29, 2024 The post Evercore ISI 2024 Emerging Biotech Conference Webcast appeared first on Orna Therapeutics.
View ArticleClik here to view.
Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
Industry Leader Brings Decades of Strategic Clinical and Cell Therapy Expertise as Orna Advances New Class of panCAR in vivo CAR RNA Medicines WATERTOWN, Mass. April 11, 2024 – Orna Therapeutics, a...
View ArticleReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting
Presentation of industry-leading T cell delivery in NHPs Oral presentation highlighting an all-RNA system enabling exon-sized genome insertions Cambridge, Mass., April 22, 2024 – ReNAgade...
View ArticleReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
GanNA founders include Carolyn Bertozzi, Ph.D., Richard D. Cummings, Ph.D., Ryan A. Flynn, M.D., Ph.D., and Namita Bisaria, Ph.D., M.B.A. Additional investment strengthens ReNAgade’s delivery platform...
View ArticleThe Endpoints 11: The biotech startups making the biggest bets with the most...
September 21, 2023 – For ReNAgade, the team is following a big vision, where the future of medicine will hinge on the advance of new RNA therapies. The post The Endpoints 11: The biotech startups...
View ArticleClik here to view.
Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to...
Unifies World-Class Validated Circular RNA and Industry-leading Delivery Technologies to Advance New Category of panCAR in vivo CAR RNA Medicines for Oncology and Autoimmune Diseases Amit Munshi to...
View ArticleReNAgade is acquired by RNA rival a year after megaround-backed launch
May 23, 2024 – Two buzzy, well-funded biotech startups are combining in a bid to create a powerhouse at the bleeding edge of genetic medicines. The post ReNAgade is acquired by RNA rival a year after...
View ArticleClik here to view.
Orna Therapeutics Appoints Nobel Laureate Carolyn Bertozzi, Ph.D., to...
WATERTOWN, Mass., July 30, 2024 – Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines, including panCAR in vivo CAR therapies for...
View Article